Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Sagimet Biosciences Inc

SGMT ✗ NOT COMPLIANT ☆ Track — members

Nasdaq · Healthcare · Biotechnology & Medical Research ·

USA Small Cap Analyst: BUY

Last Close

$10.55

▲ +13.69%

Market Cap $655.77M · Vol 763.40K

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$655.77M

Small Cap

Div Yield

N/A

EPS Growth

+27.57%

YoY

RSI (14)

81.63

Momentum

Beta

N/A

vs Market

52W High

$10.58

0.28% below

52W Low

$4.52

133.67% above

Volume

763.40K

Avg 361.70K

P/B

1.73

Price-to-book

ROE

N/A

Return on equity

Free Float

96.29%

Public shares

Shariah Compliance8 STANDARDS

✗ Sagimet Biosciences Inc (SGMT) stock is currently not Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See which standards it fails, the exact ratios behind the verdict, and halal alternatives. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does SGMT pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

+16.45%

+36.04%

+43.15%

+108.50%

YTD

+78.21%

+21.68%

-32.80%

N/A

Financials & Valuation

TTM · Annual

Total Revenue	$0.00
Net Income	$-51,038,000.00
Revenue Growth (YoY)	N/A
Gross Margin	N/A
Operating Margin	N/A
Net Profit Margin	N/A
ROE	N/A
ROA · ROIC	-36.89% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	N/A
P/B	1.73
P/FCF	N/A
EPS Growth	+27.57%
Outstanding Shares	62.16M

Technical Indicators

50-Day SMA	$7.50
200-Day SMA	$6.64
RSI (14)	81.63
Beta	N/A
52-Week High	$10.58
52-Week Low	$4.52

Volume Today	763.40K
Avg Daily Volume (30D)	361.70K
Relative Volume	2.11x
Volatility (10D)	77.69
Volatility (30D)	72.53
Free Float	96.29%

Analyst Consensus

BUY

Current Price $10.55

Mean Target $28.60

52W Low$4.52 52W High$10.58

Current

Target

$4.52 $10.58

Current Analyst target

+171.09% upside potential · 11 analysts

Identifiers

ExchangeNasdaq

FIGIBBG0020584Z8

ISINUS7867001049

CountryUnited States of America

Sub-IndustryBio Therapeutic Drugs

Earnings DateNov 13, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

2359.HK WuXi AppTec Co Ltd -2.85% ARGX.BR argenx SE -3.21% ARGX argenx SE -0.66% INSM Insmed Inc -2.05% 2269.HK WuXi Biologics (Cayman) Inc -1.27%

Company Profile

Sagimet Biosciences Inc. is a clinical-stage biopharmaceutical company developing fatty acid synthase (FASN) inhibitors that are designed to target dysfunctional metabolic and fibrotic pathways in diseases resulting from the overproduction of the fatty acid, palmitate. The Company's lead drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor in development for the treatment of metabolic dysfunction associated steatohepatitis (MASH). Denifanstat has been granted Breakthrough Therapy designation by the FDA for the treatment of non-cirrhotic MASH with moderate to advanced liver fibrosis. The Company is also exploring the use of its FASN inhibitors, which include denifanstat and its pipeline product candidate, TVB-3567, in acne and in select forms of cancer. Denifanstat is being tested in China by its license partner, Ascletis BioScience Co. Ltd., for moderate to severe acne vulgaris and recurrent glioblastoma multiforme in combination with bevacizumab.